Back to News
Market Impact: 0.4
Atsena Presents Positive 18-Month Results from Part A of the Phase 1/2/3 LIGHTHOUSE Trial Evaluating ATSN-201 in Patients with X-linked Retinoschisis
Source: GlobeNewswire
Healthcare & BiotechCompany Fundamentals
Eighteen-month Part A results from the LIGHTHOUSE trial reinforced ATSN-201's favorable safety profile and showed durable structural and functional benefits in patients with X-linked retinoschisis. The long-term clinical data de-risk the gene therapy candidate and support continued development in this rare inherited retinal disease.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.62
More News
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- Why is Nidec stock plunging today?
- Nidec Corp shares slump after auditor declines to sign off on earnings
- We're raising our Micron price target after an incredible quarter and robust guidance
- Why is Kioxia stock rallying today?